WG
CAI icon

Winton Group’s Caris Life Sciences CAI Stock Holding History

Winton Group’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$264K Buy
+14,800
New +$265K 0.01% 929
2025
Q3 		– Sell
-44,981
Closed -$1.2M – 1096
2025
Q2 		$1.2M Buy
+44,981
New +$1.21M 0.06% 371

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Winton Group's CAI Position: Q2 2026 in Review

Winton Group opened a new position in Caris Life Sciences (CAI) in Q2 2026: 14,800 shares worth $264K. The stake represents 0.01% of the portfolio and ranks #929 among its holdings. This is a return to the name: Winton Group previously reported a position in CAI as recently as Q2 2025.

Winton Group first reported a position in CAI in Q2 2025 and has held it in 2 quarters since. The position peaked at $1.2M in Q2 2025. 247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Winton Group held 14,800 shares of Caris Life Sciences worth $264K as of Q2 2026.
  • Caris Life Sciences was a new Winton Group position in Q2 2026.
  • Caris Life Sciences made up 0.01% of Winton Group's portfolio in Q2 2026, its #929 holding.
  • Winton Group first reported a position in Caris Life Sciences in Q2 2025 and has held it in 2 quarters since.
  • Winton Group's Caris Life Sciences position peaked at $1.2M in Q2 2025.
  • 247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.